Cosmo Bio CoTSE:3386 -0.55%73 FCF Yield % is 4.38 as of Jul. 09, 2026, which is 16% below its 10-year median of 5.24. GuruFocus rates TSE:3386 with a GF Score™ of 73/100 and a GF Value™ of 円1,246.90 (Fairly Valued). The stock has 4 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 76.17% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Cosmo Bio Co's FCF Yield % or its related term are showing as below:
TSE:3386'
s FCF Yield % Range Over the Past 10 Years
Min: -8.6 Med: 5.24 Max: 14.74
Current: 4.38
During the past 13 years, the highest FCF Yield % of Cosmo Bio Co was 14.74%. The lowest was -8.60%. And the median was 5.24%.
TSE:3386's FCF Yield % is ranked better than 76.17% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.32
vs TSE:3386: 4.38
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cosmo Bio Co FCF Yield % Related Terms
Cosmo Bio Co FCF Yield % Historical Data
* Premium members only.
The historical data trend for Cosmo Bio Co's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3386 vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Cosmo Bio Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co (TSE:3386) has a FCF Yield % of 4.38 as of Jul. 09, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cosmo Bio Co and its competitors. This is 16% below median its historical median of 5.24. According to the industry distribution chart, Cosmo Bio Co ranks #51 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 23.8%.
Is Cosmo Bio Co's FCF Yield % too high?
Cosmo Bio Co's current FCF Yield % of 4.38 is 16% below median its 10-year median of 5.24. Based on the distribution chart, Cosmo Bio Co ranks #51 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #51 out of 214 companies for FCF Yield %. This places Cosmo Bio Co in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Cosmo Bio Co and its competitors. Cosmo Bio Co's current FCF Yield % is 4.38, which is 16% below median its own 10-year median of 5.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,246.90, compared to a current price of 円1,262.00 — trading 1.2% above its estimated fair value. The current FCF Yield % is 4.38, which is 16% below median its 10-year median of 5.24. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current FCF Yield % is 4.38 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be overvalued.
The current stock price of 円1,262.00 is trading 1.2% above its estimated GF Value™ of 円1,246.90.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
FCF Yield %: 4.38 (16% below median its 10-year median of 5.24)
GF Value™: 円1,246.90 vs. price of 円1,262.00 (1.2% above fair value)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
